Evidence map›Paper›PMID 28592699›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2017

Lower Affinity of Isradipine for L-Type Ca

Nadine J Ortner, Gabriella Bock, Antonios Dougalis, Maria Kharitonova, Johanna Duda, Simon Hess, Petronel Tuluc, Thomas Pomberger, Nadia Stefanova, Florian Pitterl and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The L-type calcium channel CaV1.3: A potential target for cancer therapy.Journal of cellular and molecular medicine · 2024
    Review
  7. Article
  8. Article
  9. Feed-forward metabotropic signaling by Cav1 CaNeurobiology of disease · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. CaBritish journal of pharmacology · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. CACNA1C (CaNeuropharmacology · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Nadine J OrtnerDepartment of Pharmacology and Toxicology, Center for Molecular Biosciences, University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0003-3882-3283
Gabriella BockDepartment of Pharmacology and Toxicology, Center for Molecular Biosciences, University of Innsbruck, 6020 Innsbruck, Austria.
Antonios DougalisInstitute of Applied Physiology, University of Ulm, 89081 Ulm, Germany.
Maria KharitonovaDepartment of Pharmacology and Toxicology, Center for Molecular Biosciences, University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0002-8831-3321
Johanna DudaInstitute of Applied Physiology, University of Ulm, 89081 Ulm, Germany.
Simon HessBiocenter, Institute for Zoology, and Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, 50674 Cologne, Germany.
Petronel TulucDepartment of Pharmacology and Toxicology, Center for Molecular Biosciences, University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0003-3660-6138
Thomas PombergerDepartment of Pharmacology and Toxicology, Center for Molecular Biosciences, University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0002-2292-1594
Nadia StefanovaDepartment of Neurology and.ORCID 0000-0001-8188-639X
Florian PitterlInstitute of Legal Medicine and Core Facility Metabolomics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Thomas CiossekBoehringer Ingelheim Pharma GmbH & Co KG, CNS Research, 88400 Biberach an der Riss, Germany, and.ORCID 0000-0003-0724-0798
Herbert OberacherInstitute of Legal Medicine and Core Facility Metabolomics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Henning J DraheimBoehringer Ingelheim Pharma GmbH & Co KG, CNS Research, 88400 Biberach an der Riss, Germany, and.
Peter KloppenburgBiocenter, Institute for Zoology, and Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, 50674 Cologne, Germany.
Birgit LissInstitute of Applied Physiology, University of Ulm, 89081 Ulm, Germany.
Jörg StriessnigDepartment of Pharmacology and Toxicology, Center for Molecular Biosciences, University of Innsbruck, 6020 Innsbruck, Austria, joerg.striessnig@uibk.ac.at.ORCID 0000-0002-9406-7120
Universität Innsbruck · ATInnsbruck Medical University · ATUniversität Ulm · DEBoehringer Ingelheim (Germany) · DEUniversity of Cologne · DE

Funding

Austrian Science Fund FWF P 27809
6 · The paper itself

Abstract

Ca

Indexed as

AnimalsCalcium Channel BlockersCalcium Channels, L-TypeCalcium SignalingDopamineDopaminergic NeuronsIon Channel GatingIsradipineMaleMiceMice, Inbred C57BLNeuroprotective AgentsParkinson DiseaseSubstantia NigraCalcium Channel BlockersCalcium Channels, L-TypeDopamineIsradipineNeuroprotective AgentscalciumisradipineL-type calcium channelsneuroprotectionParkinson's diseasepharmacology

Identifiers

PMID28592699
PMCPMC6596555
OpenAlexW2623805123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.